Vor Biopharma Inc. (NASDAQ:VOR)
| Market Cap | 984.09M-43.8% |
| Revenue (ttm) | 0 |
| Net Income | 627.78M+137.7% |
| EPS | 11.59-115.4% |
| Shares Out | 54.19M |
| PE Ratio | 1.57 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49,509.86 |
| Open | 18.64 |
| Previous Close | 18.78 |
| Day's Range | 18.12 - 18.72 |
| 52-Week Range | 6.50 - 33.50 |
| Beta | 1.78 |
| Analysts | Buy |
| Price Target | 29.00(+59.68%) |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About VOR
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$VOR stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in VOR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VOR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VOR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VOR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VOR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VOR
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $34.86M |
| XBIState Street SPDR S&P Biotech ETF | $20.94M |
| IWMiShares Russell 2000 ETF | $18.39M |
| VXFVanguard Extended Market ETF | $11.18M |
| VTWOVanguard Russell 2000 ETF | $5.27M |
| FESMFidelity Enhanced Small Cap ETF | $4.59M |
Estimated from each fund’s disclosed top holdings × AUM
VOR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from VOR’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score